Ming Li is an accomplished biomedical researcher with significant experience in biomarker discovery and translational research. As of January 2024, Ming Li serves as Associate Director at AstraZeneca, overseeing biomarker programs in clinical trials while pursuing novel biomarker development. Prior to this, from May 2022 to October 2023, Ming Li held the position of Associate Director at Stoke Therapeutics, leading biomarker projects for Dravet Syndrome. Ming Li's expertise also includes roles as Principal Scientist at Cell Care Therapeutics and Senior Principal Scientist at Triplet Therapeutics, where impactful research focused on diabetic macular edema and Huntington’s Disease, respectively. From January 2019 to April 2021, Ming Li was a Scientist III at ImmunityBio, specializing in Natural Killer cell therapies. As a Research Assistant Professor at The Warren Alpert Medical School of Brown University, Ming Li secured multiple grants and initiated a translational research program. Educational credentials include a Ph.D. in Biological Sciences from the State University of New York at Binghamton and postdoctoral fellowship training at The Warren Alpert Medical School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices